Immune checkpoint inhibitors convey survival benefit in elderly patients with stage IV non-small cell lung cancer
Because elderly patients with non-small cell lung cancer are likely to be excluded from clinical trials due to their lower functional capacity or comorbidities, survival benefit from immune checkpoint inhibitors (ICIs) remains ...
Sep 13, 2021
0
3